CIBC Private Wealth Group
ALNY icon

CIBC Private Wealth Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

CIBC Private Wealth Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$79.7M Sell
200,425
-13,788
-6% -$6.1M 0.13% 149
2025
Q3 		$97.7M Sell
214,213
-4,116
-2% -$1.68M 0.17% 137
2025
Q2 		$71.2M Buy
218,329
+12,818
+6% +$3.55M 0.13% 162
2025
Q1 		$46.1M Buy
205,511
+2,143
+1% +$551K 0.1% 176
2024
Q4 		$48.9M Sell
203,368
-5,118
-2% -$1.35M 0.09% 174
2024
Q3 		$57.3M Buy
208,486
+2,095
+1% +$545K 0.1% 171
2024
Q2 		$52.7M Buy
206,391
+32,142
+18% +$5.07M 0.1% 168
2024
Q1 		$26.7M Buy
174,249
+548
+0.3% +$91.4K 0.05% 236
2023
Q4 		$33.2M Sell
173,701
-429
-0.2% -$73.1K 0.07% 214
2023
Q3 		$30.8M Sell
174,130
-382
-0.2% -$72.9K 0.07% 211
2023
Q2 		$33.1M Buy
174,512
+53,531
+44% +$10.6M 0.07% 218
2023
Q1 		$24.2M Sell
120,981
-885
-0.7% -$186K 0.05% 225
2022
Q4 		$28.6M Buy
121,866
+2,458
+2% +$524K 0.1% 140
2022
Q3 		$23.9M Buy
119,408
+3,166
+3% +$604K 0.06% 198
2022
Q2 		$17M Sell
116,242
-4,035
-3% -$572K 0.04% 250
2022
Q1 		$19.6M Buy
120,277
+2,025
+2% +$309K 0.04% 252
2021
Q4 		$20.1M Sell
118,252
-893
-0.7% -$166K 0.04% 259
2021
Q3 		$22.5M Buy
119,145
+429
+0.4% +$80.5K 0.05% 232
2021
Q2 		$20.1M Sell
118,716
-7,544
-6% -$1.1M 0.05% 255
2021
Q1 		$17.8M Buy
+126,260
New +$19M 0.04% 262
2018
Q2 		– Sell
-5
Closed -$1K – 1949
2018
Q1 		$1K Sell
5
-7,550
-100% -$973K ﹤0.01% 1836
2017
Q4 		$960K Buy
+7,555
New +$949K ﹤0.01% 660

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

CIBC Private Wealth Group's ALNY Position: Q4 2025 in Review

CIBC Private Wealth Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 6.4% in Q4 2025, selling an estimated $6.1M and leaving 200,425 shares worth $79.7M. The position accounts for 0.13% of the portfolio, ranked #149.

CIBC Private Wealth Group first reported a position in ALNY in Q4 2017 and has held it in 22 quarters since. The position peaked at $97.7M in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • CIBC Private Wealth Group held 200,425 shares of Alnylam Pharmaceuticals worth $79.7M as of Q4 2025.
  • CIBC Private Wealth Group sold 13,788 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $6.1M.
  • Alnylam Pharmaceuticals made up 0.13% of CIBC Private Wealth Group's portfolio in Q4 2025, its #149 holding.
  • CIBC Private Wealth Group first reported a position in Alnylam Pharmaceuticals in Q4 2017 and has held it in 22 quarters since.
  • CIBC Private Wealth Group's Alnylam Pharmaceuticals position peaked at $97.7M in Q3 2025.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.